Haiyan Lei

6PUBLICATIONS
100CO-AUTHORS
Molecular targetsCellular nervous systemApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 04, 2024
ASAP1 and ARF1 Regulate Myogenic Differentiation in Rhabdomyosarcoma by Modulating TAZ Activity.

Katie E Hebron, Olivia L Perkins, Angela Kim

|Aug 24, 2023
Inhibition of NAD+-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models.

Grace B McKay-Corkum, Victor J Collins, Choh Yeung

|Jul 03, 2023
Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma.

Srivandana Akshintala, R Taylor Sundby, Donna Bernstein

|Jan 04, 2023
HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype.

Man Xu, Ming Sun, Xiyuan Zhang

|Nov 02, 2022
The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models.

Katie E Hebron, Xiaolin Wan, Jacob S Roth

|Oct 27, 2022
A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma.

John A Ligon, R Taylor Sundby, Mary F Wedekind

Pageof 1